跳至主要内容
临床试验/NCT00371813
NCT00371813已完成3 期

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Multinational Study Of Efficacy And Safety Of Varenicline Tartrate For Smoking Cessation

Pfizer15 个研究点 分布在 3 个国家目标入组 334 人开始时间: 2006年9月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Pfizer
入组人数
334
试验地点
15
主要终点
To compare 12 weeks of treatment with varenicline 1 mg BID to placebo for smoking cessation, and to evaluate continuous abstinence from smoking for 12 weeks after the treatment period.

研究概览

简要总结

To investigate safety and efficacy of varenicline tartrate in helping people quit smoking

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Current cigarette smokers between the ages of 18 and 75 years, who are motivated to stop smoking

排除标准

  • Patients currently suffering from depression, or have been diagnosed with depression in the last 12 months, or subjects with past or present history of psychosis, panic disorder, or bipolar disorder
  • Any subject with known severe chronic obstructive pulmonary disease (COPD)

结局指标

主要结局

To compare 12 weeks of treatment with varenicline 1 mg BID to placebo for smoking cessation, and to evaluate continuous abstinence from smoking for 12 weeks after the treatment period.

次要结局

  • To gather safety data for 12 weeks of treatment with varenicline 1 mg BID or placebo followed by 12 weeks of non-treatment follow-up.

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (15)

Loading locations...

相似试验